医疗ETF（159828）涨超1.0%，政策红利与创新疗法驱动板块估值修复

Group 1 - The pharmaceutical and biotechnology sector has increased by 25.02% this year, ranking 4th among 31 industries in the Shenwan index, with a current PE valuation of 31.31 times, at the historical median level [1] - Sub-sectors such as medical services, chemical pharmaceuticals, and medical devices have shown significant gains of 6.60%, 3.80%, and 2.22% respectively in the past week [1] - The National Healthcare Security Administration has issued a temporary measure for disease-based payment management, promoting payment reform and standardizing total budget management and disease payment standard calculations [1] Group 2 - The preliminary list of innovative drugs for medical insurance and commercial insurance for 2025 has been released, with several cancer drugs and chronic disease new drugs expected to see rapid growth after being included in the dual directory [1] - The medical device sector continues to receive policy support for innovation, with a recommendation to focus on niche areas such as brain-computer interfaces [1] - Under the release of industry policy dividends, there are investment opportunities in innovative drugs, CXO, and medical equipment sectors [1] Group 3 - The medical ETF (159828) tracks the CSI Medical Index (399989), which can have a daily fluctuation of up to 20%, reflecting the overall performance of listed companies involved in medical devices, medical services, and medical information technology [1] - The index primarily consists of companies in the pharmaceutical and biotechnology industry, while also including a small number of companies in the computer and beauty care sectors, focusing mainly on small and mid-cap enterprises [1]